Marius Nacht
Founder & Anchor Investor @ aMoon Fund
Tel Aviv-yafo, Israel
Marius Nacht is a Series A investor at aMoon Fund in Tel Aviv-yafo focused on Artificial Intelligence and Machine Learning. Marius Nacht is based out of Tel Aviv-yafo, Tel Aviv, and is the Owner of Nacht Family Office. Marius previously worked at Check Point Software Technologies as Chairman and Founder. Marius Nacht attended Tel Aviv University.
- Total investments:
- 34
- Last investment:
- Lead investor:
- 47%
Last updated:
For AI agents: llms.txt
Industries Marius Nacht invests in
Stages Marius Nacht invests in
Countries Marius Nacht invests in
Round sizes
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Round size
- Seed
- $630k–$120M
- Series A
- $5M–$23M
- Series B
- $8M–$83M
Investment Focus
Industry
- Artificial Intelligence 10 (29%)
- Machine Learning 7 (21%)
- Health Care 6 (18%)
- Cyber Security 5 (15%)
- Medical 4 (12%)
Stage
- Series A 13 (38%)
- Series B 6 (18%)
- Seed 5 (15%)
- Venture - Series Unknown 5 (15%)
- Angel 1 (3%)
Country
- Israel 14 (41%)
- United States 9 (26%)
- Germany 1 (3%)
- Switzerland 1 (3%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| CPTx develops single-stranded DNA products to neutralize viruses and address infectious diseases. | $29M / Venture - Series Unknown / Sep 12, 2024 | ||
| WaveBL is a digital platform using proprietary blockchain technology to transfer electronically trade documents. The WaveBL solution enables the instant, encrypted, and authenticated transfer of electronic Bills of Lading and related trade documents. The platform complies with universal processes and regulations in use. The platform is designed tomeet the needs of all parties involved in trade, including shipping companies, agents, brokers, and banks. WaveBL has strong alliances with leading companies in global trade to drive faster digitalization and adoption. | $37M / Series B / Jun 06, 2023 | ||
| Wisdo is an AI-powered Social Health platform harnessing the power of data and meaningful connections to improve health. | $5M / Series A / Jan 05, 2023 | ||
| CommonGround-AI provides a new 3D video platform. | $25M / Series A / Nov 30, 2022 | ||
| Ultima Genomics is unleashing the power of genomics at scale. Ultima Genomics drives the scale of genomic information to enable unprecedented advances in biology and improvements in human health. | $600M / Venture - Series Unknown / May 31, 2022 | ||
| BioGenCell designs cellular therapies that treat blood flow problems in the limbs, a side effect of diabetes and heart disease. Its technology creates autologous cells, derived from the patients themselves, to repair themselves. Its lead product, BC1, uses the company's technology to treat blood vessel insufficiency that can cause multipleorgan failure in diabetic patients. Derived from the patient's own adult stem cells, its easy-to-use and cost-effective therapies can regenerate damaged tissues, with the eventual goal of treating a wide range of degenerative diseases including diabetes, heart failure, stroke, blindness, cancer, and immunological diseases. Its patented technology platform provides a comprehensive solution for most aspects of cellular therapy and supports rapid manufacturing and long-term storage (bio-banking) of therapeutic cellular products for use in patient treatment. | $16M / Seed / May 09, 2022 | ||
| WINT - Water Intelligence developing advanced solutions for smart water management and control. The company detects and stops leaks at the source using Artificial Intelligence. It is used in commercial and industrial facilities, offices, homes, and apartments. It also prevents water damage caused by leaks, broken pipes or malfunctioning watersystems.WINT customers gain deep insights about their water use to identify water waste and reduce consumption by 25%. They manage water and detect leaks using artificial intelligence and pattern matching technologies, combining high accuracy metering with advanced data analytics. WINT solutions protect global real estate portfolios and homes by revealing leaks and identifying water savings opportunities.WINT was founded in 2011 and is headquartered in New York, USA. | $15M / Series B / Jan 11, 2022 | ||
| GrayMatters Health delivers beyond the pill digital therapeutics for mental disorders through self-neuromodulation of brain processes. | $10M / Series A / Jan 11, 2022 | ||
| 1E Therapeutics is a breakthrough, drug development company creating RNA-targeting therapeutics based on a proprietary drug design platform. | $120M / Seed / Dec 08, 2021 | ||
| TriEye is the pioneer of mass-market, CMOS-based Short-Wave infrared (SWIR) sensing solutions. Based on advanced academic research, TriEye’s breakthrough and proprietary technology enables cost-effective, high-resolution image data and depth perception in all weather and lighting conditions. Founded in 2017, the company’s cutting-edge technologyallows perception systems to operate and deliver reliable image data and actionable information, while reducing expenditure by up to 1,000x the existing industry rates. | $74M / Series B / Nov 10, 2021 | ||
| See all 34 investments → | |||
Co-Investors
About aMoon Fund
aMoon is a leading healthtech & life sciences venture fund founded by Marius Nacht and Dr. Yair Schindel. Their team is passionate about building successful businesses and helping biopharma, digital health and medical technology companies realize their potential. They partner with management teams who use technology and cutting-edge science toaccelerate cures for the world’s most life-threatening conditions and those providing solutions for global healthcare’s biggest cost drivers.
aMoon Fund Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Moshe Mor
General Partner
|
|||
|
Gur Roshwalb
Managing Director
|
|||
Itay Bengad
Executive in Residence
|
|||
|
Marius Nacht
Founder & Anchor Investor
|
|||
Michal Goren Miller
Chief Legal Counsel & Chief Compliance Officer
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Marius Nacht invest in?
Marius Nacht invests primarily in Artificial Intelligence, Machine Learning and Health Care startups, most often at Series A and Series B stage. Most of the 34 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Marius Nacht invest in?
Marius Nacht typically joins rounds of $630k–$120M at Seed, $5M–$23M at Series A and $8M–$83M at Series B. These are whole funding-round sizes, not Marius Nacht's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Marius Nacht took part in.
How do I contact Marius Nacht?
Public channels for Marius Nacht include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Marius Nacht last invest?
The most recent investment recorded for Marius Nacht closed in Sep 2024. Shizune tracks 34 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
